1 Healthcare resource utilization and direct medical costs associated with index and recurrent infection: A real-world data analysis.

2 2019 update of the WSES guidelines for management of () infection in surgical patients.

3 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

4 antimicrobial use, human gut microbiota and clostridium difficile colonization and infection

5 applying fecal microbiota transplantation (fmt) to treat recurrent clostridium difficile infections (rcdi) in children

6 Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

7 Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

8 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

9 Community-acquired Clostridium difficile infection: an increasing public health threat

10 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

11 Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

12 Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

13 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

14 Community-acquired Clostridium difficile infection: an increasing public health threat

15 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

16 Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection.

17 Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance

18 Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

19 Clostridium difficile infection in fever patients with gynecological malignancies

20 Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection

21 Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

22 Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship

23 Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

24 Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

25 A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)

26 Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study

27 Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections

28 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

29 Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

30 Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection

31 Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis

32 Pathway to Prevention of Nosocomial Clostridium difficile Infection

33 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

34 Prevention of Clostridium difficile Infection With Probiotics

35 Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection

36 Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

37 Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients

38 Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS

39 Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

40 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

41 Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015

42 severe clostridium difficile infections. a systematic literature -review-

43 clostridium difficile infection outbreak in a male rehabilitation ward, hong kong (china), 2011

44 biofilm structures in a mono-associated mouse model of clostridium difficile infection

45 application of antibody-mediated therapy for treatment and prevention of clostridium difficile infection

46 treating clostridium difficile infections: should fecal microbiota transplantation be reclassified from investigational drug to human tissue?

47 anaerobically cultivated human intestinal microbiota as first-line treatment for clostridium difficile infection

48 refractory clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin

49 reducing the risk of severe complications among patients with clostridium difficile infection

50 prevalence of clostridium difficile infection among the patients attending a tertiary care teaching hospital

51 clostridium difficile infection and proton pump inhibitor use in hospitalized pediatric cystic fibrosis patients

52 emergence of community-acquired clostridium difficile infection: the experience of a french hospital and review of the literature

53 low risk of irritable bowel syndrome after clostridium difficile infection

54 Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

55 Comparison of clinical severity score indices for Clostridium difficile infection

56 Is primary prevention of Clostridium difficile infection possible with specific probiotics?

57 Predictors of Death after Clostridium difficile Infection: A Report on 128 Strain-Typed Cases from a Teaching Hospital in the United Kingdom

58 Fidaxomicin versus vancomycin for Clostridium difficile infection

59 Health Care-Associated Clostridium difficile Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality

60 Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)

61 The Impact of ICD-9-CM Code Rank Order on the Estimated Prevalence of Clostridium difficile Infections

62 Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection

Keyword Connections

Journals

Research Groups

Bibliographies